CLINUVEL Strategic Update – Extended
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More
APPENDIX 4C AND ACTIVITY REPORT
KEY HIGHLIGHTS: SEPTEMBER QUARTER 2020 • Cash receipts of $12,015,000 • Operating...
Read More
CLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More
Afamelanotide for Acute Stroke Patients
EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...
Read More
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read More
Media Release – TGA approves Australian drug to protect patients from light and sun
New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...
Read More
Australian TGA approves SCENESSE®
Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...
Read More
Update: SCENESSE® in DNA Repair
CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...
Read More
Further Research Coverage Initiated on CLINUVEL
CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies...
Read More
Appendix 4G and Corporate Governance Statement
Download Appendix 4G and Corporate Governance Statement
Read More
CLINUVEL Annual General Meeting 2020
CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...
Read More
SCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read More
CLINUVEL News & Facts site live
Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL...
Read More